Format

Send to

Choose Destination
Chest. 2010 Jun;137(6):1405-9. doi: 10.1378/chest.09-2406. Epub 2010 Jan 15.

Clinical outcome for cystic fibrosis patients infected with transmissible pseudomonas aeruginosa: an 8-year prospective study.

Author information

1
Manchester Adult Cystic Fibrosis Centre, University Hospitals South Manchester NHS Foundation Trust, Southmoor Rd, Manchester, M23 9LT, England. andrew.jones@uhsm.nhs.uk

Abstract

BACKGROUND:

Although there is now compelling evidence for cross-infection by strains of Pseudomonas aeruginosa at some specialist (cystic fibrosis [CF]) centers, the clinical impact of infection by transmissible strains is unclear.

METHODS:

In an 8-year prospective study, we compared the clinical outcome of two groups of patients with CF infected by transmissible (n = 28) and sporadic strains (n = 52) of P aeruginosa.

RESULTS:

There were no differences between the two groups in survival, annual changes in spirometry, or BMI. There were differences in requirements for IV antibiotic treatment (mean [SD]: 29.3 [21.9] days vs 53.1 [32.5] days) and hospitalization (median [range]: 11.6 [1.1, 49.3] days vs 23.3 [5.5, 103.6] days) between patients infected with sporadic and transmissible strains of P aeruginosa, respectively.

CONCLUSIONS:

We conclude that infection by transmissible P aeruginosa does not increase mortality but is associated with increased health-care and antibiotic use for patients with CF.

PMID:
20081099
DOI:
10.1378/chest.09-2406
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center